• Saltar a la navegación principal
  • Saltar al contenido principal
  • Saltar al pie de página
ILAPHAR | Revista de la OFIL

ILAPHAR | Revista de la OFIL

Revista de la Organización de Farmacéuticos | Ibero-latinoamericanos | Ibero Latin American Journal of Health System Pharmacy

  • Números de la revista
  • Sobre la Revista
  • Eventos y Publicaciones

Use of cyclic TPN in patients with impaired liver function

Liñana Granell C, Montañés Pauls B, García Martínez T, Ibáñez Benages E

Hospital General Universitario de Castellón. Castellón de la Plana (España)

____

Rev. OFIL 2016, 26;3:171-174

Fecha de recepción: 30/10/2015  –  Fecha de aceptación: 29/11/2015

____

SUMMARY

Liver disorders and biliary system are common complications in patients receiving parenteral nutrition (PN) long term. Elevated gamma-GT, alkaline phosphatase and bilirubin are the most specific markers of liver disease associated with the PN. Strategies for the treatment of liver complications from parenteral nutrition are: adjust the caloric intake of the PN (carbohydrates and lipids), use of PN cyclic and early use of enteral nutrition. As part of our regarding prescription and preparation of the PN daily activity, it was observed that there was a group of patients with PN prolonged whose liver profiles within normal in the beginning, got worse during the period of artificial nutrition. The head of nutrition clinical pharmacist made a series of recommendations to reverse that failure in liver function. In this series of 8 cases it shows how, at the time that the cyclized nutrition starts, the hepatic disease associated with PN significantly begins to reverse. This is demonstrated by comparing pre- and post-liver cyclization analytical parameters.

Key Words: Total parenteral nutrition, liver disease, cyclic infusion.

____

Download PDF article: Uso de la nutrición parenteral total cíclica en pacientes con deterioro de la función hepática

Footer

Footer 1

ISSN Edición impresa: 1131-9429
ISSN Edición electrónica: 1699-714X

Web diseñada y desarrollada por Company Valor